ArticleDiscover oncology2026
LINC00886 inhibits the proliferation, migration, and invasion of NSCLC cells by sponging miR-141-5p.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the impact of LINC00886 on the prognosis of patients with non-small cell lung cancer (NSCLC) and its regulatory effects on cancer cells.
methodsA total of 184 NSCLC patients were enrolled. Postoperative tissues were preserved in liquid nitrogen. Kaplan - Meier (KM) survival curves were used to assess 5-year overall survival. Multivariate cox regression analysis was performed to identify independent prognostic factors for NSCLC. RT-qPCR detected gene expression levels. CCK-8 and Transwell assays evaluated cell proliferation, migration, and invasion. Dual-luciferase reporter assays validated the interaction between LINC00886 and miR-141-5p.
resultsOur study revealed that LINC00886 was markedly downregulated in both NSCLC tissues and cell lines. This reduced expression was significantly associated with larger tumor diameters and advanced TNM stages. Multivariate analysis identified LINC00886 as an independent protective factor for NSCLC patients, with its downregulation portending a lethal outcome. In vitro, ectopic expression of LINC00886 significantly attenuated the proliferation, migration, and invasion of NSCLC cells. We further identified miR-141-5p, which was upregulated in NSCLC, as a direct target gene of LINC00886. Critically, rescue experiments demonstrated that miR-141-5p mimics could abrogate the inhibition of LINC00886 overexpression on NSCLC cell function.
conclusionLINC00886 inhibits NSCLC cell proliferation, migration, and invasion through miR-141-5p, thereby suppressing NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.